Citadel Advisors
CARM

Citadel Advisors’s Carisma Therapeutics CARM Stock Holding History

Citadel Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-38,973
Closed -$88.5K – 14318
2024
Q1 		$88.5K Buy
+38,973
New +$93.6K ﹤0.01% 11513
2023
Q1 		– Sell
-1,102
Closed -$13.4K – 14763
2022
Q4 		$13.4K Sell
1,102
-53
-5% -$557 ﹤0.01% 13445
2022
Q3 		$10K Buy
+1,155
New +$15.7K ﹤0.01% 12275
2022
Q2 		– Sell
-5,519
Closed -$63.2K – 12948
2022
Q1 		$67K Sell
5,519
-28,806
-84% -$402K ﹤0.01% 12606
2021
Q4 		$560K Buy
34,325
+13,819
+67% +$278K ﹤0.01% 9415
2021
Q3 		$325K Buy
20,506
+16,555
+419% +$794K ﹤0.01% 10888
2021
Q2 		$365K Sell
3,951
-11,468
-74% -$731K ﹤0.01% 10786
2021
Q1 		$802K Buy
15,419
+12,329
+399% +$582K ﹤0.01% 8639
2020
Q4 		$83K Sell
3,090
-3,564
-54% -$90.4K ﹤0.01% 10327
2020
Q3 		$187K Buy
6,654
+2,116
+47% +$42.3K ﹤0.01% 8861
2020
Q2 		$65K Buy
4,538
+503
+12% +$6.78K ﹤0.01% 9191
2020
Q1 		$45K Sell
4,035
-909
-18% -$14.9K ﹤0.01% 9076
2019
Q4 		$103K Buy
4,944
+3,858
+355% +$88.7K ﹤0.01% 8535
2019
Q3 		$25K Sell
1,086
-1,393
-56% -$32.6K ﹤0.01% 8888
2019
Q2 		$74K Buy
2,479
+1,677
+209% +$50.2K ﹤0.01% 8621
2019
Q1 		$17K Sell
802
-1,276
-61% -$22K ﹤0.01% 9087
2018
Q4 		$59K Buy
2,078
+1,198
+136% +$38.2K ﹤0.01% 8444
2018
Q3 		$38K Sell
880
-1,403
-61% -$54.7K ﹤0.01% 8862
2018
Q2 		$89K Buy
+2,283
New +$101K ﹤0.01% 8286
2018
Q1 		– Sell
-769
Closed -$12K – 8294
2017
Q4 		$12K Sell
769
-368
-32% -$6.84K ﹤0.01% 7885
2017
Q3 		$36K Buy
+1,137
New +$31.8K ﹤0.01% 7254
2017
Q2 		– Sell
-1,480
Closed -$65K – 7512
2017
Q1 		$65K Buy
+1,480
New +$61.7K ﹤0.01% 6982
2016
Q4 		– Sell
-553
Closed -$31K – 7278
2016
Q3 		$31K Buy
+553
New +$41.2K ﹤0.01% 6950

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's CARM Position: Q2 2024 in Review

Citadel Advisors sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 38,973 shares — an estimated $88.5K sold.

Citadel Advisors first reported a position in CARM in Q3 2016 and held it in 23 quarters. The position peaked at $802K in Q1 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • Citadel Advisors reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 38,973 Carisma Therapeutics shares in Q2 2024, an estimated $88.5K.
  • Citadel Advisors first reported a position in Carisma Therapeutics in Q3 2016 and held it in 23 quarters.
  • Citadel Advisors's Carisma Therapeutics position peaked at $802K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.